Lipid Nanoparticles Development Summit Europe on September 24-26, 2024 in Berlin, Germany

The spotlight continues to shine on lipid nanoparticles as the 'go-to' delivery vehicle, however the demand remains to translate learnings from vaccine LNP-mRNA success into therapeutic applications. Positioned as a delivery vehicle with no ceiling to innovation, drug developers across the field are continuing to progress research to target the previously unreachable and treating the undruggable. Pinpoint the lipid components and structural complexities, advance formulative strategy and streamline manufacture to revolutionise your LNP design.

The 3rd Lipid Nanoparticles Development Summit Europe is your premier forum to collaborate with a carefully curated community of experts across Discovery, Characterisation, Translatability, Formulation, Biodistribution, Manufacturing and much more. These industry leaders are gathering in Berlin this September to bring the greatest challenges in LNP development to the fore, tackling them head on to ensure 2024 is the year of the LNP.

Join us this September address your unanswered questions and drive your development of LNPs to the next level, supercharging innovation in your approach to safe, stable and targeted drug delivery.

URLs:
Tickets: https://go.evvnt.com/2504387-1?pid=10008
Brochure: https://go.evvnt.com/2504387-3?pid=10008

Time: 8:30 AM - 4:00 PM

Prices:

Drug Developer - Conference + 1 Workshop: EUR 3131.00,

Drug Developer - Conference + 2 Workshops: EUR 3464.00,

Drug Developer - Full Access: Conference + 3 Workshops: EUR 3797.00,

Academic - Conference + 1 Workshop: EUR 2665.00,

Academic - Conference + 2 Workshops: EUR 2930.00,

Academic - Full Access: Conference + 3 Workshops: EUR 3197.00,

Solution Provider - Conference + 1 Workshop: EUR 3799.00,

Solution Provider - Conference + 2 Workshops: EUR 4198.00,

Solution Provider - Full Access: Conference + 3 Workshops: EUR 4597.00

Speakers: Alexander Kros, Professor, Leiden University, Christian Plank, Chief Technology Officer, Ethris, Daniel Tondera, Head of Biology, Pantherna Therapeutics, Dimitrios Lamprou, Professor, Queen's University Belfast, Emily Young, Non-Viral Formulation Lead, 4basebio, Jens Bæk Simonsen, Independent Scientific Consultant, Jbsimonsen Consult, Jeremie Parot, Research Scientist, SINTEF, Joanna Grudzinska-Goebel, DMPK Project Lead/ Immunogenicity Expert, Bayer AG, Kinkini Roy, Associate Director, Aviceda Therapeutics, Laura Breda, Scientific Co-Director Children’s Hospital of Philadelphia, Roland Bottger, Senior Research Scientist, CureVac, Selma Pereira Lopes, Head of Drug Product Development Leiden, Johnson and Johnson Innovative Medicine, Sandipan Dawn, Principal Scientist, Ocular Therapeutix, Laurent Strodiot, Director, R and D, GSK, Rongjun Chen, Professor Imperial College, London, Robert Worsham, Senior Director, Manufacturing Science and Technology, Insmed, Martino Alfredo, Cappelluiti Post-Doctoral Researcher, San Raffaele Telethon Institute for Gene Therapy, Mostafa Nakach, Global Head of Process Engineering for Biologic Drug Product Development, Sanofi, Neill Liptrott, Professor of Pharmacology and Immunocompatibility, University of Liverpool, Richard Campbell, Senior Lecturer, University of Manchester